BR112022026279A2 - Métodos de tratamento de alergia usando anticorpos anti-bet v 1 - Google Patents
Métodos de tratamento de alergia usando anticorpos anti-bet v 1Info
- Publication number
- BR112022026279A2 BR112022026279A2 BR112022026279A BR112022026279A BR112022026279A2 BR 112022026279 A2 BR112022026279 A2 BR 112022026279A2 BR 112022026279 A BR112022026279 A BR 112022026279A BR 112022026279 A BR112022026279 A BR 112022026279A BR 112022026279 A2 BR112022026279 A2 BR 112022026279A2
- Authority
- BR
- Brazil
- Prior art keywords
- bet
- antibodies
- treatment methods
- allergy
- allergy treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/16—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39575—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from other living beings excluding bacteria and viruses, e.g. protozoa, fungi, plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Botany (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063047126P | 2020-07-01 | 2020-07-01 | |
| US202063129253P | 2020-12-22 | 2020-12-22 | |
| PCT/US2021/039945 WO2022006305A1 (en) | 2020-07-01 | 2021-06-30 | Methods of treating allergy using anti-bet v 1 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022026279A2 true BR112022026279A2 (pt) | 2023-02-14 |
Family
ID=77168400
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022026279A BR112022026279A2 (pt) | 2020-07-01 | 2021-06-30 | Métodos de tratamento de alergia usando anticorpos anti-bet v 1 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11897945B2 (https=) |
| EP (1) | EP4175986A1 (https=) |
| JP (1) | JP2023531968A (https=) |
| KR (1) | KR20230030573A (https=) |
| CN (1) | CN115698059A (https=) |
| AU (1) | AU2021300129A1 (https=) |
| BR (1) | BR112022026279A2 (https=) |
| CA (1) | CA3177918A1 (https=) |
| CL (1) | CL2022003744A1 (https=) |
| IL (1) | IL299207A (https=) |
| MX (1) | MX2022015677A (https=) |
| WO (1) | WO2022006305A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL298034B2 (en) * | 2017-06-01 | 2024-05-01 | Regeneron Pharma | Antibodies against BET V 1 and methods of using them |
| CA3177918A1 (en) | 2020-07-01 | 2022-01-06 | Amanda ATANASIO | Methods of treating allergy using anti-bet v 1 antibodies |
| WO2024251358A1 (en) * | 2023-06-07 | 2024-12-12 | Mabylon Ag | Anti-allergen antibodies and uses thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994010194A2 (de) | 1992-10-27 | 1994-05-11 | Biomay Produktions- Und Handelsgesellschaft M.B.H. | MOLEKÜLFRAGMENTE (PEPTIDE) DER HAUPTALLERGENE DER POLLEN VON BÄUMEN DER ORDNUNG $i(FAGALES) |
| WO1994014475A1 (en) | 1992-12-21 | 1994-07-07 | Tanox Biosystems, Inc. | ALLERGEN-SPECIFIC IgA MONOCLONAL ANTIBODIES AND RELATED PRODUCTS FOR ALLERGY TREATMENT |
| EP0619323A1 (en) | 1993-04-09 | 1994-10-12 | Schering-Plough | Human monoclonal antibodies and processes and materials for making such antibodies |
| GB0002386D0 (en) | 2000-02-02 | 2000-03-22 | Novartis Nutrition Ag | Therapeutic composition |
| US6849259B2 (en) | 2000-06-16 | 2005-02-01 | Symphogen A/S | Polyclonal antibody composition for treating allergy |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| DK1219299T4 (da) | 2000-12-28 | 2011-02-14 | Biomay Ag | Allergivacciner og fremstilling deraf |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| WO2005103081A2 (en) | 2004-04-20 | 2005-11-03 | Genmab A/S | Human monoclonal antibodies against cd20 |
| ITMI20052517A1 (it) | 2005-12-29 | 2007-06-30 | Lofarma Spa | Varianbtio ipoallergeniche dell'allergene maggiore bet v 1 di polline di betula verrucosa |
| AT503297B1 (de) | 2006-05-18 | 2007-09-15 | Biomay Ag | Allergen-spezifische antikörper |
| TW201920262A (zh) | 2013-07-30 | 2019-06-01 | 美商再生元醫藥公司 | 抗活化素ａ之抗體及其用途 |
| US10935554B2 (en) | 2013-08-23 | 2021-03-02 | Regeneron Pharmaceuticals, Inc. | Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (SIT) |
| TWI756187B (zh) | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | 抗ｌａｇ３抗體及其用途 |
| IL298034B2 (en) | 2017-06-01 | 2024-05-01 | Regeneron Pharma | Antibodies against BET V 1 and methods of using them |
| TWI838389B (zh) | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAｘ抗-CD3抗體及其用途 |
| CA3177918A1 (en) | 2020-07-01 | 2022-01-06 | Amanda ATANASIO | Methods of treating allergy using anti-bet v 1 antibodies |
| US20250263471A1 (en) | 2024-01-30 | 2025-08-21 | Regeneron Pharmaceuticals, Inc. | Methods of treating allergy using anti-bet v 1 antibodies |
-
2021
- 2021-06-30 CA CA3177918A patent/CA3177918A1/en active Pending
- 2021-06-30 BR BR112022026279A patent/BR112022026279A2/pt unknown
- 2021-06-30 WO PCT/US2021/039945 patent/WO2022006305A1/en not_active Ceased
- 2021-06-30 JP JP2022579724A patent/JP2023531968A/ja active Pending
- 2021-06-30 AU AU2021300129A patent/AU2021300129A1/en active Pending
- 2021-06-30 MX MX2022015677A patent/MX2022015677A/es unknown
- 2021-06-30 US US17/364,299 patent/US11897945B2/en active Active
- 2021-06-30 EP EP21749400.4A patent/EP4175986A1/en active Pending
- 2021-06-30 KR KR1020227043651A patent/KR20230030573A/ko active Pending
- 2021-06-30 CN CN202180043390.9A patent/CN115698059A/zh active Pending
- 2021-06-30 IL IL299207A patent/IL299207A/en unknown
-
2022
- 2022-12-23 CL CL2022003744A patent/CL2022003744A1/es unknown
-
2023
- 2023-12-19 US US18/545,795 patent/US12583914B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CL2022003744A1 (es) | 2023-06-02 |
| JP2023531968A (ja) | 2023-07-26 |
| US20240209074A1 (en) | 2024-06-27 |
| US12583914B2 (en) | 2026-03-24 |
| IL299207A (en) | 2023-02-01 |
| AU2021300129A1 (en) | 2022-12-08 |
| MX2022015677A (es) | 2023-02-22 |
| CA3177918A1 (en) | 2022-01-06 |
| EP4175986A1 (en) | 2023-05-10 |
| WO2022006305A1 (en) | 2022-01-06 |
| US20220002394A1 (en) | 2022-01-06 |
| CN115698059A (zh) | 2023-02-03 |
| KR20230030573A (ko) | 2023-03-06 |
| US11897945B2 (en) | 2024-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022026279A2 (pt) | Métodos de tratamento de alergia usando anticorpos anti-bet v 1 | |
| BR112014008764A8 (pt) | Usos de um anticorpo, anticorpo, composição farmacêutica e combinação para o tratamento de artrite reumatoide | |
| BR112021019107A2 (pt) | Anticorpos contra amiloide-beta piroglutamato e usos dos mesmos | |
| BR112019023754A2 (pt) | anticorpo anti-sirpalpha ou um fragmento de ligação ao antígeno do mesmo, composição farmacêutica, e, combinação do anticorpo anti-sirpalpha ou da composição farmacêutica. | |
| BR112022000719A2 (pt) | Anticorpo anti-tau ou um fragmento de ligação ao antígeno do mesmo, polinucleotídeo, vetor de expressão, célula hospedeira, método para produção do anticorpo anti-tau ou fragmento de ligação ao antígeno do mesmo, hibridoma, composição farmacêutica, composição para diagnosticar uma doença neurológica degenerativa, kit, uso do anticorpo ou fragmento de ligação ao antígeno do mesmo e método para prevenir ou tratar uma doença neurológica degenerativa | |
| BR112013004056B8 (pt) | Anticorpos monoclonais ab anti-n3pglu projetados por humano, seu uso e composição farmacêutica que os compreende | |
| BR112021023487A2 (pt) | Moléculas de ligação anti-tdp-43 e usos das mesmas | |
| BR112015021979A2 (pt) | Anticorpos humanos para grem1 | |
| BR112018009064A8 (pt) | anticorpo de pd-l1, fragmento de ligação ao antígeno do mesmo e aplicação médica do mesmo | |
| BR112022012437A2 (pt) | Método de tratamento de um câncer compreendendo a administração de uma molécula biespecífica pd-1 x lag-3 a um indivíduo em necessidade deste e método de tratamento de um câncer em um indivíduo | |
| BRPI0821658B8 (pt) | anticorpo monoclonal humano ou um fragmento de ligação ao antígeno do mesmo que se liga a hnkg2d e seus usos | |
| BR112022023088A2 (pt) | Anticorpos contra sars-cov-2 e métodos de seleção e uso dos mesmos | |
| BR112021016398A2 (pt) | Anticorpos cd33 e métodos de uso dos mesmos para tratar o câncer | |
| BR112023023453A8 (pt) | Anticorpo anti-tigit ou um fragmento de ligação ao antígeno deste, composições farmacêuticas e usos do referido anticorpo anti-tigit ou um fragmento de ligação ao antígeno deste | |
| EA202191666A1 (ru) | Антитела к il-27 и их применение | |
| BR112022026533A2 (pt) | Anticorpo anti-fxi/fxia, fragmento de ligação do mesmo, e antígenos e uso farmacêutico do mesmo | |
| MA37670A1 (fr) | Anticorps anti-transglutaminase 2 | |
| BR112022026999A2 (pt) | Anticorpos anti-il-36r para tratamento de dermatoses neutrofílicas | |
| BR112021021281A2 (pt) | Anticorpo monoclonal que se liga especificamente ao gitr | |
| BR112022001395A2 (pt) | Métodos para administrar anticorpos anti-siglec-8 e corticosteroides | |
| BR112015012708A2 (pt) | anticorpos para bmp-6 | |
| BR112023025767A2 (pt) | Anticorpo ou fragmento de ligação a antígeno do mesmo e seu uso, molécula de ácido nucleico, vetor de expressão, célula hospedeira, composição farmacêutica, doença ou distúrbio relacionado ao vírus sincicial respiratório e método para tratar e/ou prevenir doenças ou distúrbios relacionados ao mesmo, método para detectar a presença de um vírus sincicial respiratório ou uma quantidade do mesmo em uma amostra e kit para detectar o mesmo | |
| BR112021025077A2 (pt) | Anticorpos anti-sortilina para uso em terapia | |
| BR112023001061A2 (pt) | Anticorpos antiabeta | |
| BR112022004302A2 (pt) | Anticorpos anti-il-27 e usos dos mesmos |